BETTER-B SIGNED
BETTER TREATMENTS FOR BREATHLESSNESS IN PALLIATIVE AND END OF LIFE CARE
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0BETTER-B project word cloud
Explore the words cloud of the BETTER-B project. It provides you a very rough idea of what is the project "BETTER-B" about.
Project "BETTER-B" data sheet
The following table provides information about the project.
| Coordinator |
KING'S COLLEGE LONDON
Organization address contact info |
| Coordinator Country | United Kingdom [UK] |
| Total cost | 3˙791˙503 € |
| EC max contribution | 3˙769˙999 € (99%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SC1-2018-Single-Stage-RTD |
| Funding Scheme | RIA |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-01-01 to 2022-12-31 |
Partnership
Take a look of project's partnership.
Map
Project objective
The BETTER-B consortium tests whether mirtazapine, currently used as an antidepressant, is an effective treatment to reduce chronic or refractory breathlessness (CB) in patients with advanced chronic obstructive pulmonary or interstitial lung disease (COPD or ILD) needing palliative care or at the end of life.
Our focus is on breathlessness that persists despite optimal treatment of the underlying condition. This widespread and frightening symptom has a major detrimental impact on patients’ quality of life and distresses their family, friends and carers. It is associated with physical and psychosocial morbidity and results in high use of health care services, including emergency care.
There are no licenced medicines for CB in the world. It is a major challenge to clinical management, care quality and patient wellbeing. We have completed a feasibility trial in 60 patients, reviews and case studies that suggest mirtazapine is a promising treatment.
To assess if mirtazapine is effective, we conduct a randomised double blind clinical trial of mirtazapine versus placebo in patients with CB and COPD or ILD. The trial recruits 324 patients over 18 months across respiratory, palliative care and community services in Poland, Ireland, Italy, Germany and the UK. We study the effects of treatment over time on patients, their family or caregivers and care costs. We survey clinicians and produce accessible European guidance on treating CB.
The consortium unites a unique multi-disciplinary group of clinician scientists from respiratory, palliative, geriatric and rehabilitation fields, alongside statisticians, trialists, health economists, health care researchers, patient and consumer groups and a European Society. This ensures the optimal design and operation of the trial and the widest impact from its results.
Using an existing medicine for a different purpose offers a highly cost-effective approach for treatment that can be implemented and sustained internationally.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BETTER-B" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "BETTER-B" are provided by the European Opendata Portal: CORDIS opendata.